ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
Rhea-AI Summary
ClearPoint Neuro (NASDAQ:CLPT) announced that its Velocity Alpha MR High Speed Surgical Drill System has received CE Marking, adding to existing FDA 510(k) clearance in the US.
The Adeor Medical–manufactured drill integrates with ClearPoint’s SmartFrame platform to support multi-trajectory neurosurgical, cell, and gene therapy procedures and broaden the company’s global drug delivery ecosystem.
Positive
- Velocity Alpha MR High Speed Surgical Drill receives CE Marking in Europe
- Drill already holds FDA 510(k) clearance in the United States
- System integrates with SmartFrame navigation to support multi-trajectory neurosurgical procedures
- CE Marking supports global expansion of ClearPoint Neuro’s drug delivery ecosystem
Negative
- None.
News Market Reaction – CLPT
In the May 14 session, CLPT gained 4.76%, reflecting a moderate positive market reaction. Argus tracked a peak move of +11.6% during that session. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Earnings date notice | Neutral | +8.1% | Announced timing and webcast details for Q1 2026 results release. |
| Apr 22 | Device FDA clearance | Positive | -2.2% | Reported FDA 510(k) clearance and first clinical use of Velocity Alpha drill. |
| Apr 20 | Canadian approval | Positive | -3.9% | Health Canada license for Neuro Navigation System enabling Canadian procedures. |
| Mar 17 | Earnings results | Positive | -13.9% | Reported record 2025 revenue, growth, guidance, and cash position alongside losses. |
| Mar 06 | Earnings date notice | Neutral | +8.1% | Set date and call details for Q4 and full-year 2025 results release. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive milestones (regulatory clearances and strong 2025 growth) often saw negative next-day moves, while neutral earnings-date notices produced notable gains.
Over the last few months, ClearPoint Neuro has combined strong growth with multiple regulatory and geographic expansions. On Mar 17, 2026, it reported record 2025 revenue of $37.0M and issued 2026 guidance of $52.0–$56.0M, yet shares fell 13.93%. Subsequent Canadian approval for its navigation system on Apr 20 and FDA clearance plus first clinical use of the Velocity Alpha drill on Apr 22 also drew negative price reactions. In contrast, two earnings-date scheduling releases on Mar 6 and Apr 29 led to gains of 8.11% and 8.12%, respectively. Today’s CE Mark news extends the same drug-delivery ecosystem and global footprint theme.
Key Terms
CE Marking regulatory
FDA 510(k) clearance regulatory
pneumatic drill system technical
cell and gene therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that the Velocity Alpha® MR High Speed Surgical Drill System has received CE Marking in addition to the existing FDA 510(k) clearance in the United States.
The Velocity Alpha MR High Speed Surgical Drill System is manufactured by German-based surgical equipment leader Adeor Medical AG. It is a versatile pneumatic drill system designed to streamline ClearPoint procedures and improve case efficiency in both MR and operating room environments. The drill is purpose-built to uniquely integrate with ClearPoint Neuro's SmartFrame navigation platform, featuring specialized drill bits and cutters that further differentiate it from conventional surgical drills. Designed to support multi-trajectory procedures, including investigational cell and gene therapy cases, the system integrates into complex neurosurgical workflows, offering scalability and potential to support a broader range of programs within the Company's partnered biologics portfolio.
"Approval of this drill in Europe underscores the Company's strategy to expand its integrated product portfolio with complementary technologies designed to enhance procedural workflows, strengthen the ClearPoint Neuro ecosystem, and support long-term growth," said Jeremy Stigall, Chief Business Officer & General Manager of Biologics & Drug Delivery at ClearPoint Neuro. "With both FDA clearance and CE Marking of the drill, we believe this solution provides a pathway to support neurosurgical procedures globally."
About the Velocity Alpha MR High Speed Surgical Drill System
The Velocity Alpha MR High Speed Surgical Drill System is FDA 510(k) cleared in the United States and CE Marked for use in trephination, incision, cutting, removal, shaping, and sawing of soft and hard tissue, bone, and biomaterials in or near a magnetic field of 3.0 Tesla or less for use in Neurosurgery. A universal cutter system with one-click coupling and integrated telescoping functionality is designed to support the needs of today's OR personnel. The system is designed for ease of handling and operates at up to 80,000 rpm with a low noise profile.
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Forward Looking Statements
This press release contains forward-looking statements within the context of the federal securities laws, including the Company's expectation for the future market of the Velocity Alpha MR High Speed Surgical Drill System, and the product's other performance and results, including the product's ability to reduce procedural time, streamline complex workflows, enhance overall case efficiency, and advance commercial adoption of therapies. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's ability to maintain its current relationships with biologics and drug delivery partners or enter into new relationships with such partners; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of the Company's new products. For a detailed description of the Company's risks and uncertainties, you are encouraged to review its documents filed with the SEC including the Company's recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contact:
Investor Relations:
Danilo D'Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
SOURCE: ClearPoint Neuro, Inc.
View the original press release on ACCESS Newswire